SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Equipment >

Imagin Medical Inc. (IMEXF)

IMEXF RSS Feed
Add IMEXF Price Alert      Hide Sticky   Hide Intro
Moderator: jb1965
Search This Board: 
Last Post: 11/22/2017 4:27:26 PM - Followers: 10 - Board type: Free - Posts Today: 0





 

 

Overview

 Imagin Medical is a medical imaging company
Imagin Medical will establish a new standard of care in the detection and removal of cancer using endoscopes by commercializing an advanced, proprietary and patented imaging technology
 Initially targeting bladder cancer 
 Thereafter expanding to all minimally invasive surgical (MIS) procedures where endoscopes are used
 

Benefits of Minimally Invasive Surgery (MIS)

• Performed using tiny holes or incisions (less muscle cut)
• Reduced pain, smaller / no scarring
• Quicker recovery, shorter hospital stay, less expensive
• Minimally invasive surgeries performed using endoscopes














 


Endoscopic Primer

• Endoscopic means “to look inside”
• Endoscope – a medical device with attached light used to look inside organs
• Endoscopy performed when other tools, such as an MRI, X-ray, or CT scan, are inappropriate
• Endoscopies commonly performed to diagnose cancer, take tissue samples for biopsies, and to remove cancer
• Different medical specialties use different types of endoscopes
• Cystoscopes, Bronchoscopes, Gastroscopes, Laparoscopes
   










 

Endoscopic Market
 
 $46B growing global endoscopy market
 $1B is spent annually in US alone on bladder cancer surveillance
 Bladder cancer is 3rd most common in men and 6th most common in US overall with recurrence rate of 40 – 70% making it the most expensive cancer to treat over the lifetime of a patient
 4 million estimated urology endoscopy procedures performed each year targeting bladder cancer
 Imagin’s disruptive imaging technology squarely addresses limitations in:
• Endoscopies targeting bladder cancer (cystoscopies)
• Endoscopies targeting many other cancers


 


 

Endoscope Limitations - White Light

• Current endoscopes use “white light” (or visible light) that has been the gold standard for decades
• Highly effective for detecting protruding cancerous tumors
• Limitations of white light:
• Tumors that are flat may look the same as normal tissue
• Not effective in visualizing the edges of the tumor
• Inability to illuminate tumors beneath skin surface


 

Endoscope Limitations - Blue Light

• Blue light cystoscopes (white light with blue filter) used with contrasting agents induce fluorescence and improve ability to detect flat cancers and visualize edges
• Drawbacks of existing blue light technology:
• Requires one hour for the agent to be absorbed by bladder
• Surgeon must manually “switch” between white light and blue light to see tumor area
• Repeated usage of imaging agent causes adverse side-effects (FDA limits use of contrast agents to one-time use per patient)
 

 
Disruptive Technology - Endoscopes with i/Blue Imaging System

• Significantly reduced prep time with bladder absorption in less than 15 minutes vs. one hour
• Optics 100,000 X more sensitive
• Simultaneous acquisition of differing images
• No switching back and forth
• Blends the white light and fluorescence images into one
• Enables the surgeon to better visualize and resect the cancer
• This advancement makes i/Blue technology practical, not only for the O.R. but also potentially for the physicians’ office
• Adapts seamlessly to most types of endoscopes on the market
 
Future Development - i/Vision Imaging System

• Incorporates multiple illumination sources in one system
• Accommodates the most commonly used fluorescing contrast agents, i.e., such as those based on the emission of Protoporphyrin IX (PpIX) and Indocyanine green (ICG)
• This instrument enables expansion into multiple endoscopic procedures such as laparoscopic (general and gynecology), colorectal, thoracic and gastroenterology procedures related to cancer and non-cancerous conditions
• Like i/Blue, blends two images into one, adapts to most endoscopes, and orders of magnitude more sensitive
 
Future Development - i/Red Imaging System

• Requires no contrasting agents - uses the fluorescence produced by the body and tumor itself
• Contrast between normal and cancer tissue is potentially related to difference in porphyrin content within the cells
• Dramatically expands the market to endoscopic procedures where imaging agents cannot be practically administered
• Like i/Blue, blends two images into one, adapts to most endoscopes, orders of magnitude more sensitive
 
Intellectual Property

• Underpinning company’s technology are three issued patents and two pending patent applications on technology related to near-infrared spectroscopic imaging for cancer and other medical applications obtained, under exclusive license, from Lawrence Livermore National Security, LLC
• Aim of licensing agreement is to commercialize the technology invented by Dr. Stavros Demos, a key advisor to the company


 
Product Development Roadmap


 
Why Invest in Imagin Medical?

• Key investment risks removed, high investment return potential
• Disruptive cutting edge imaging technology will dramatically reduce bladder cancer recurrence rates addressing $1B growing global market
• Limited R&D risks as concept is proven – this is an execution play
• Experienced medical device management team that has done it before
• Management in medical device field for over 30 years
• Worked together in previous companies
• High-margin product with strong clinical and economic advantages
• Commercial launch expected in 2018 with positive operating cash flows
• Strong acquisition market
• Most medical device companies grow by acquisition, not organically
• Company expected to have significant value with multiple liquidity options
 

 
Number of Shares Outstanding as at August 31, 2017:                50,068,739
 
Shares Subject to Resale Restrictions    
1) Shares subject to escrow (1,725,000 released every 6 months - Feb 9 & Aug 9) 5,175,000  
2) Performance shares 5,000,000  
Total Shares Subject to Resale Restrictions   10,175,000
Total Tradeable Float   39,893,739
Total Shares Outstanding   50,068,739

Number of Warrants Outstanding as at August 31, 2017:             25,005,064
 
Warrants Outstanding    
Feb 2016 Private Placement Strike @ 0.35 - expire Feb 9, 2018 7,007,413
Q4/2016 PP - Tranche 1 Strike @ 0.12 / 0.16 - expire Oct 20, 2018 5,111,300
Q4/2016 PP - Tranche 2 Strike @ 0.12 / 0.16 - expire Dec 9, 2018 3,980,565
Warrants from BSS acquisition Strike @ 0.15 - expire Feb 9, 2019 8,905,786
Total Warrants Outstanding   25,005,064

Number of Options Outstanding as at August 31, 2017:                3,350,000
 
 Management Options Outstanding    
Tranche 1 Strike @ 0.15 3,350,000
Total Options Outstanding   3,350,000
 
Various Company Links

Company Web Site
Corporate Presentation (10/2/2017)

CSE Web Site for Imagin Medical
SEDAR Web Site for Imagin Medical

Listing Statement CSE - February 16, 2016

Share Issuance - February 9, 2016
Share Issuance - August 22, 2016
Share Issuance - October 21, 2016
Share Issuance - December 13, 2016
Convertible Debt Issuance - March 3, 2017
Share Issuance - October 4, 2017

Option Grant - June 30, 2016
Option Grant - December 19, 2016
Option Grant - April 10, 2017

Information Circular - October 31, 2016

Monthly CSE Filings (CSE Form 7)
 
  2016 2017
January N/A Link
February Link Link
March Link Link
April Link Link
May Link Link
June Link Link
July Link Link
August Link Link
September Link  
October Link  
November Link  
December Link  

Financial Statements (FS) & Management Discussion and Analyses (MD&A)
 
      2015 2016 2017
Q2 Quarter Ended March 31 FS   Link Link
MD&A   Link Link
Q3 Quarter Ended June 30 FS   Link Link
MD&A   Link Link
Q4 Quarter Ended September 30 FS Link Link  
MD&A Link Link  
Q1 Quarter Ended December 31 FS Link Link  
MD&A Link Link  

 

 
SureTrader
Interactive Brokers Advertisement
IMEXF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#408   Right on target according to my medical contacts. MSU 11/22/17 04:20:51 PM
#406   Thank you very interesting. kcjones 11/19/17 05:51:32 PM
#405   Latest Corp presentation 7Card 11/19/17 12:14:11 PM
#404   Remember these words. Imagin's i/Blue will be the 7Card 11/14/17 12:12:29 PM
#403   There is zero about your posts that tells AMG 11/13/17 08:54:54 PM
#402   Not me. I said GREAT investment. Retirement $$ SO75 11/13/17 08:09:35 PM
#401   Might.be.a.good company.eventually.but.way.too much.risk.at.this price after the Neverending 11/13/17 06:48:48 PM
#400   The prospectus here is mighty rich compared to AMG 11/13/17 01:35:33 PM
#399   Should.be.headed.lower.If.this tech even.works FDA.approval.will take YEARS! I d Neverending 11/13/17 01:31:00 PM
#398   How does someone who literally pumps 2 Bankrupt AMG 11/13/17 12:35:37 PM
#397   I.see.it.going.back to 6c. shortly.No point holding this junk. Neverending 11/13/17 11:55:28 AM
#396   It.is.likely.a.penny.stock.scam.in the DUMP.phase of a.pump a dump.scam operatio Neverending 11/13/17 11:25:15 AM
#395   Who? I'll tell you who. It's many of AMG 11/13/17 11:09:04 AM
#394   Who in he** said this was a good investment? MSU 11/13/17 09:54:54 AM
#393   You forgot .05 SO75 11/07/17 06:03:35 PM
#392   6-10 10-14 12-13...now 8? You guys/gals got anymore AMG 11/07/17 05:16:22 PM
#391   You are being real generous, it looks more MSU 11/07/17 12:46:07 PM
#390   Told.ya.it.would.sell-off! Expect.50% of gains to.be.retraced to about 12-13c Neverending 11/07/17 11:06:37 AM
#389   Strength in a .15 cent stock lol... MSU 11/07/17 10:12:09 AM
#388   The strength in this name has been nothing jb1965 11/06/17 10:33:30 PM
#387   https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aIME-2525843&symbol=IME&regio lithiumjr 11/06/17 09:40:17 AM
#386   $IMEXF in the news !! lithiumjr 11/06/17 09:29:33 AM
#385   Haha nice try never ending. U do ILuvblo2 11/04/17 07:26:59 PM
#384   Need you be reminded merely one week ago AMG 11/04/17 04:06:26 PM
#381   Stock topped off today.and.failed.to maintain its highs so Neverending 11/03/17 10:33:27 PM
#380   Lith, exactly right. Imagin already knows their 7Card 11/03/17 01:29:39 PM
#379   I fully expect results from the first of lithiumjr 11/03/17 01:12:20 PM
#378   Another new 52wk high for IMEXF of 19.3c 7Card 11/03/17 12:42:22 PM
#377   It's on next week !!... lithiumjr 11/03/17 10:42:09 AM
#376   Thx 7Card. JPak 11/03/17 07:19:57 AM
#375   No reason why this won't go to several 7Card 11/03/17 12:35:07 AM
#374   Nice recap someone posted here : lithiumjr 11/02/17 06:45:50 PM
#373   Does this mean they've been buying stock? Campeese 11/02/17 06:04:45 PM
#372   By the way, I think $1 would be 7Card 11/02/17 05:25:02 PM
#371   Great day for IMEXF and IME. Love 7Card 11/02/17 05:23:14 PM
#370   The study is expected to take 3 mos 7Card 11/02/17 05:21:13 PM
#369   This company going to get bought out and lithiumjr 11/02/17 03:53:14 PM
#368   Timeline Could someone please clarify timeline. JPak 11/02/17 03:46:35 PM
#367   Options Granted 18 and 19 cents , going lithiumjr 11/02/17 03:21:16 PM
#366   That guy is a stockhouse poster SO75 11/02/17 01:38:44 PM
#365   Not the only one hearing rumors... lithiumjr 11/02/17 01:11:48 PM
#364   With all these buys @.20+ this thing could SO75 11/02/17 12:37:02 PM
#363   We're going to 30 ! Soon lithiumjr 11/02/17 10:28:08 AM
#362   IMEXF approved for DTC is very good news. 7Card 11/02/17 02:21:02 AM
#361   Most likely any news will be out simultaneously lithiumjr 11/01/17 10:17:36 PM
#360   Still waiting for the rumor tho. Any word SO75 11/01/17 09:13:24 PM
#359   $IMEXF Those thinking of getting in, grab em lithiumjr 11/01/17 08:33:36 PM
#358   Yep new high on the canadian market also lithiumjr 11/01/17 03:57:14 PM
#357   IMEXF hits new 52wk high today at 16c. 7Card 11/01/17 03:28:19 PM
#356   Building a nice base @.20. SO75 11/01/17 11:36:05 AM
PostSubject